Vanguard Capital Management’s MapLight Therapeutics MPLT Stock Holding History
Bought
Maintained
Sold
Other funds holding MPLT
BBA
Vanguard Capital Management's MPLT Position: Q3 2026 in Review
Vanguard Capital Management reduced its MapLight Therapeutics (MPLT) stake by 49% in Q3 2026, selling an estimated $7.28M and leaving 396,076 shares worth $4.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3147.
Vanguard Capital Management first reported a position in MPLT in Q1 2026 and has held it in 3 quarters since. The position peaked at $28.1M in Q2 2026. 98 funds tracked by Wall St. Rank hold MPLT as of Q3 2026.
- Vanguard Capital Management held 396,076 shares of MapLight Therapeutics worth $4.04M as of Q3 2026.
- Vanguard Capital Management sold 388,074 MapLight Therapeutics shares in Q3 2026, an estimated $7.28M.
- MapLight Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3147 holding.
- Vanguard Capital Management first reported a position in MapLight Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's MapLight Therapeutics position peaked at $28.1M in Q2 2026.
- 98 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.